Uta Ishikawa
Higher Degree by Research Candidate
South Australian Immunogenomics Cancer Institute
Faculty of Health and Medical Sciences
Holds a Bachelor’s degree in Biomedical Sciences from the Federal University of Rio Grande do Norte, Brazil, with a background in undergraduate research on cancer and inflammation, focusing on nanoparticle-based cancer therapy.
Currently pursuing a Master’s degree by research at the South Australian Immunogenomics Cancer Institute (SAIGENCI), within the BioImmunoEngineering Laboratory (BIEL). Research focuses on the development of lipid-polymer nanodiscs for mRNA delivery in cancer immunotherapy, aiming to enhance therapeutic efficacy.
Research interests include nanomedicine, immunotherapy, and drug delivery systems, particularly in oncology.
-
Language Competencies
Language Competency English Can read, write, speak and understand spoken Japanese Can read, write, speak, understand spoken and peer review Portuguese Can read, write, speak, understand spoken and peer review -
Research Interests
-
Journals
Year Citation 2023 Holandaa, A. G. A., Cesario, B. C., Silva, V. M., Francelino, L. E. C., Nascimento, B. H. M., Damascenoa, K. F. A., . . . Queiroza, G. F. (2023). Use of Cold Atmospheric Plasma in the Treatment of Squamous Cell Carcinoma:<i> in</i><i> vitro</i> Effects and Clinical Application in Feline Tumors: A Pilot Study. TOPICS IN COMPANION ANIMAL MEDICINE, 53-54, 10 pages.
2022 Silva, F. S., Costa de Souza, K. S., Galdino, O. A., de Moraes, M. V., Ishikawa, U., Medeiros, M. A., . . . de Oliveira, M. F. (2022). Hyperbaric oxygen therapy mitigates left ventricular remodeling, upregulates MMP-2 and VEGF, and inhibits the induction of MMP-9, TGF-β1, and TNF-α in streptozotocin-induced diabetic rat heart. LIFE SCIENCES, 295, 10 pages.
2021 Cavalcante, R. S., Ishikawa, U., Silva, E. S., Silva-Junior, A. A., Araujo, A. A., Cruz, L. J., . . . de Araujo Junior, R. F. (2021). STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer. BRITISH JOURNAL OF PHARMACOLOGY, 178(11), 2284-2304.
Connect With Me
External Profiles
